Tirzepatide Muscle Loss & Lean Mass: SURMOUNT-1 DXA Evidence

“Does tirzepatide cause muscle loss?” is one of the most-searched patient questions about Zepbound and Mounjaro therapy, and the honest answer is more nuanced than the viral TikTok framing suggests. Yes, a portion of weight lost on tirzepatide is lean tissue rather than fat — this is now well-documented in the SURMOUNT-1 DXA substudy^[1]published in 2025. But the lean-tissue percentage of total weight loss is COMPARABLE to non-pharmacological rapid weight loss and to bariatric surgery, not a uniquely drug-induced phenomenon. The Zepbound and Mounjaro prescribing information do not list muscle loss, sarcopenia, or myopathy as labeled adverse reactions. What matters more than the drug choice is whether the patient is doing the two interventions with the strongest evidence for preserving muscle in a caloric deficit: resistance training 2-3 days per week and adequate protein. Here is the full evidence map, with every PMID verified against live PubMed E-utilities on 2026-05-24.

At a glance

• SURMOUNT-1 DXA substudy^[1] (Look 2025, n=160): on tirzepatide, body weight fell 21.3%, fat mass fell 33.9%, and lean mass fell 10.9% at Week 72.
• Of the weight lost, approximately 75% was fat mass and 25% was lean mass — on both tirzepatide AND placebo arms.
• The 75/25 split was consistent across sex, age (under 50, 50-65, 65+), and tertiles of total weight lost in post-hoc subgroup analysis.
• Retatrutide body composition substudy^[4] (Coskun 2025) explicitly concluded that the proportion of lean mass loss to weight loss was similar to other obesity treatments — consistent with tirzepatide and semaglutide.
• Neither the Zepbound nor Mounjaro DailyMed prescribing information lists muscle loss, sarcopenia, or myopathy as a labeled adverse reaction.
• The protective interventions: resistance training 2-3 days per week, 1.2-1.6 g/kg protein per day (up to 1.6-2.0 g/kg on a GLP-1 per Stefanakis 2024^[8]), and avoiding overly aggressive rate of weight loss.

What “muscle loss on tirzepatide” actually means (DXA fat vs lean mass)

When someone loses weight — whether on tirzepatide, on semaglutide, after bariatric surgery, on a very-low-calorie diet, or in caloric restriction without any intervention — the weight that comes off is not pure body fat. It is a mix of fat mass and lean tissue, where “lean tissue” on a dual-energy X-ray absorptiometry (DXA) scan includes skeletal muscle, organ tissue, bone-attached connective tissue, and intracellular water in lean compartments. The classic body composition ratio for moderate-rate weight loss in mixed-age adults is roughly 75% fat mass and 25% lean mass. Faster weight loss tilts the ratio toward more lean tissue lost; slower weight loss with high protein and resistance training tilts it toward more fat.

Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes, both made by Eli Lilly) produces 15-22.5% total body weight loss in the SURMOUNT-1 pivotal trial^[2] over 72 weeks at the 15 mg dose. The composition of that weight loss is the relevant clinical question, and the SURMOUNT-1 DXA substudy^[1] is the primary peer-reviewed source.

The framing matters. “Tirzepatide causes muscle wasting” is misleading. “Tirzepatide produces large weight loss, and the composition of that weight loss follows the same physiology as any rapid weight loss — meaning a portion is lean tissue, and the percentage can be optimized with resistance training and protein” is the accurate version.

What the SURMOUNT-1 body-composition substudy showed

Look and colleagues^[1] published the SURMOUNT-1 DXA body composition substudy in Diabetes, Obesity and Metabolism in 2025. SURMOUNT-1 was the pivotal Phase 3 trial of tirzepatide in adults with obesity over 72 weeks. The DXA substudy enrolled 160 of the 2,539 main-trial participants (124 pooled tirzepatide, 36 placebo) and measured fat mass and lean mass at baseline and Week 72. The key results:

• Total body weight reduction: −21.3% on tirzepatide vs −5.3% on placebo at Week 72 (p < 0.001).
• Total fat mass reduction: −33.9% on tirzepatide vs −8.2% on placebo (p < 0.001).
• Total lean mass reduction: −10.9% on tirzepatide vs −2.6% on placebo (p < 0.001).
• Composition of weight lost: approximately 75% fat mass and 25% lean mass on BOTH tirzepatide and placebo arms — the standard body composition ratio for moderate-rate weight loss in healthy-physiology adults.
• Subgroup consistency: the 75/25 split remained consistent across sex (73% female cohort), age (less than 50, 50 to less than 65, 65 or older), and tertiles of total body weight reduction (15.3 kg or less, more than 15.3 to 25.9 kg, more than 25.9 kg).

The placebo arm showing the same 75/25 fat-to-lean ratio is the critical observation. It supports the conclusion that the body composition split is NOT a tirzepatide-specific pharmacological effect but a generic consequence of the rate and total amount of weight lost. The drug is doing what any meaningful caloric deficit does, with the absolute magnitude of weight loss (driven by tirzepatide's appetite-suppression mechanism) being the differentiating factor.

How tirzepatide compares to retatrutide and semaglutide on lean mass

Cross-drug comparison gives the next layer of context. Coskun and colleagues^[4] published the retatrutide body composition substudy in Lancet Diabetes & Endocrinology in 2025. Retatrutide is the triple-agonist (GIP/GLP-1/glucagon) successor to tirzepatide in Eli Lilly's pipeline. The Phase 2 substudy in adults with type 2 diabetes (n=189 enrolled, n=103 with paired baseline + Week 36 DXA) reported:

• Retatrutide 8 mg pooled: 26.1% reduction in total fat mass at Week 36 (vs 4.5% on placebo, p < 0.0001).
• Retatrutide 12 mg: 23.2% fat mass reduction.
• Dulaglutide 1.5 mg comparator: 2.6% fat mass reduction (similar to placebo).
• Authors' conclusion: “The proportion of lean mass loss to weight loss was similar to other obesity treatments. These findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss.”

Semaglutide DXA data comes primarily from the STEP program. Wilding 2021 STEP-1^[5] reported 14.9% total body weight loss at Week 68 in adults with overweight or obesity without diabetes. Wadden 2021 STEP-3^[6] reported 16.0% body weight loss when semaglutide was combined with intensive behavioural therapy (compared with 5.7% on placebo). Published cross-trial DXA estimates for semaglutide land in the same 25-40% lean-tissue-of-TBWL range as tirzepatide, with the same caveat that the absolute kilograms of lean tissue lost depend on total weight loss.

The clinically important takeaway: tirzepatide, semaglutide, and retatrutide all appear to produce similar body composition SPLITS (roughly 75/25 fat to lean), with the differentiating factor being the TOTAL magnitude of weight loss each drug achieves. For our full head-to-head comparison, see the tirzepatide vs semaglutide head-to-head evidence review and the retatrutide vs tirzepatide head-to-head evidence.

How tirzepatide compares to bariatric surgery on lean mass

Bariatric surgery has historically produced the largest weight losses available outside of starvation protocols. Roux-en-Y gastric bypass and sleeve gastrectomy typically produce 25-35% total body weight loss at 12-24 months, with body composition substudies consistently reporting a 70-80% fat / 20-30% lean ratio of weight lost. Cava and colleagues^[9] reviewed this cross-modality evidence in Advances in Nutrition and reported that the proportion of weight lost as lean tissue across all weight-loss modalities (caloric restriction, intermittent fasting, bariatric surgery, very-low-calorie diets, and pharmacotherapy) clusters in the 20-40% range for rapid weight loss and the 15-30% range for slower weight loss.

Stefanakis and colleagues^[8] reviewed the impact of weight loss on fat-free mass, muscle, bone, and hematopoiesis in Metabolism in 2024 and reached the same conclusion: the lean tissue loss seen on tirzepatide and other GLP-1-based therapies is on the same magnitude as bariatric surgery and very-low-calorie diets at the equivalent total weight loss. The active mitigation strategies (resistance training, protein, slower rate of loss) are also the same across modalities.

For patients deciding between tirzepatide and bariatric surgery, muscle loss is NOT a meaningful differentiator. The decision rests on other factors: durability of weight loss, side effect profile, cost, surgical risk, and patient preference. Our bariatric surgery vs GLP-1 decision guide walks through the full comparison.

Resistance training during tirzepatide treatment — what the evidence shows

The single highest-evidence intervention for preserving lean mass during weight loss is resistance training. Murphy and Koehler^[10] published a meta-analysis and meta-regression in Scandinavian Journal of Medicine & Science in Sports in 2022 examining the effect of energy deficiency on lean mass and strength gains from resistance training. The pooled finding: energy deficiency impairs lean mass gains from resistance training (effect size attenuated relative to energy balance) but does NOT impair strength gains — meaning patients can still get stronger in a caloric deficit, and resistance training still attenuates lean mass loss in a deficit relative to no training.

The practical translation for tirzepatide patients: resistance training will not allow you to gain meaningful muscle while in the 21% body weight deficit produced by tirzepatide 15 mg, but it WILL meaningfully reduce the proportion of weight lost that is lean tissue. The Murphy 2022 meta-regression suggests the magnitude of lean mass preservation is dose-dependent on training frequency and intensity, with 2-3 sessions per week of compound lifts at moderate-to-high effort producing the clearest signal.

Practical prescription, from the broader resistance-training evidence base referenced in our companion exercise pairing on a GLP-1 evidence review:

• 2-3 resistance training sessions per week, 45-60 minutes per session.
• 8-10 exercises targeting major muscle groups, prioritizing compound lifts: squat, hinge (deadlift or Romanian deadlift), horizontal push (dumbbell press or push-up), horizontal pull (row or pull-up), and carry (farmer carry or sled push).
• 8-12 reps per set, 2-4 sets per exercise, with progressive overload week to week.
• Cardio is helpful for cardiometabolic health but does not preserve muscle the way resistance training does. Combine both if possible; do not substitute cardio for resistance training if lean mass preservation is the goal.

Protein intake on tirzepatide — practical targets

Stefanakis and colleagues^[8] 2024 review explicitly called out the increased protein requirements during GLP-1 therapy. The recommended targets:

• General weight loss: 1.2-1.6 g/kg body weight per day for adults in a caloric deficit who want to preserve lean mass.
• On a GLP-1 (tirzepatide, semaglutide): 1.6-2.0 g/kg body weight per day, with the higher end of the range recommended for older adults and patients with aggressive weight loss goals.
• Distribution: 3-4 meals per day with 25-40 g of protein each, hitting the per-meal threshold (~0.25-0.40 g/kg) for maximal muscle protein synthesis stimulation.

For a 75 kg adult, that means 90-150 g of protein per day, distributed as 25-40 g per meal across 3-4 daily meals. The practical challenge on tirzepatide is meeting this target on a suppressed appetite. Many patients drop daily caloric intake by 30-50% on tirzepatide without explicitly tracking protein, ending up at 50-70 g/day when their target should be 90-150 g. Protein-first meal sequencing (eat protein before carbs and fats at each meal) helps when fullness comes early in a meal.

Our GLP-1 protein & macro calculator gives a personalized target. For specific food choices that hit the threshold dose efficiently, see our what to eat on a GLP-1 protein guide and the best protein powder for weight loss on a GLP-1 evidence review. For protein timing specifically, see the when to drink protein shakes for weight loss (female-focused evidence).

Why this matters more in perimenopausal and older patients

The clinical stakes of lean mass loss are highest in adults over 65 and in perimenopausal women. Older adults are already at risk of sarcopenia (age-related muscle loss starting in the fourth decade and accelerating after 60), fragility fractures, and loss of functional independence. Perimenopausal women face accelerated sarcopenia driven by estrogen decline, which impairs muscle protein synthesis independently of caloric intake or training.

Stefanakis and colleagues^[8] reviewed the bone-and-muscle-implications evidence base specifically for emerging obesity pharmacotherapies and recommended:

• DXA monitoring is standard, not optional in adults over 65 and in perimenopausal women. Baseline DXA scan plus follow-up every 6 months to track lean mass and bone mineral density.
• Structured resistance training is required rather than recommended. Working with a credentialed exercise physiologist or physical therapist for the first 4-12 weeks of training to establish safe form is reasonable.
• Protein target is at the upper end of the range (1.6-2.0 g/kg body weight per day).
• Slower rate of loss may be preferred. The 0.5-1.0% body weight per week target is appropriate; aggressive deficits producing 1.5-2% per week in older adults or perimenopausal women disproportionately remove lean tissue and bone.
• Fall risk should be tracked. Lean mass loss plus weight loss can transiently impair balance.

What the Zepbound and Mounjaro FDA labels say about muscle loss

Neither the Zepbound (tirzepatide for obesity) nor the Mounjaro (tirzepatide for type 2 diabetes) DailyMed prescribing information lists muscle loss, sarcopenia, myopathy, or lean mass reduction as a labeled adverse reaction in Section 6 (Adverse Reactions). The body composition shifts during weight loss are characterized as a consequence of weight reduction rather than a direct drug pharmacological effect.

The Mounjaro DailyMed SetID is d2d7da5d-ad07-4228-955f-cf7e355c8cc0 and the Zepbound prescribing information is searchable via the DailyMed portal. Both labels list the same Section 6 adverse reactions: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity, eructation, hair loss, gastroesophageal reflux disease, and a small number of other reactions. The SURMOUNT-1 DXA substudy^[1] is the primary peer-reviewed source clinicians reference for the magnitude of lean mass change during tirzepatide treatment, and that substudy is referenced in the broader prescribing-information narrative on body composition rather than as a labeled adverse event.

For the full FDA-label decoding, see our Mounjaro/Zepbound FDA prescribing information explained article.

What about tirzepatide withdrawal? SURMOUNT-4 evidence

Aronne and colleagues^[3] published SURMOUNT-4 in JAMA in 2024. The trial enrolled adults who had achieved meaningful weight loss on tirzepatide during a 36-week open-label lead-in period, then randomized them to continued tirzepatide vs placebo for an additional 52 weeks. The continued-tirzepatide group lost an additional 5.5% of body weight; the placebo (withdrawal) group regained 14.0% of body weight, for a net 19.5 percentage-point difference between arms at Week 88.

The body composition implications: substantial weight regain after tirzepatide withdrawal, and the composition of regained weight in observational follow-up tends to be disproportionately fat mass rather than lean tissue. This is the standard pattern seen after any weight-loss intervention is stopped — regained weight rarely fully restores baseline lean tissue, especially without active resistance training. The implication is that active resistance training during AND after a tirzepatide cycle is the most important intervention for preserving body composition trajectory regardless of whether the drug is continued.

Practical takeaway

• Muscle loss on tirzepatide is real but PROPORTIONAL to the rate and total amount of weight lost — not a uniquely pharmacological effect. Neither the Zepbound nor Mounjaro FDA label lists muscle loss as a labeled adverse reaction.
• The SURMOUNT-1 DXA substudy^[1] (the highest- quality body composition data on tirzepatide) showed roughly 75% of weight lost was fat mass and 25% was lean tissue at Week 72 — the SAME split was observed in the placebo arm, confirming the ratio reflects weight-loss physiology rather than a drug-specific effect.
• Cross-drug comparison: retatrutide^[4], semaglutide^[5][6], and bariatric surgery all produce a similar fat-to-lean split (roughly 75/25). The differentiating factor between drugs is total magnitude of weight loss, not body composition quality.
• Resistance training 2-3 days per week is the single highest- evidence protective intervention. Murphy 2022 meta-analysis^[10] showed energy deficiency impairs lean mass gains but not strength gains — you can still get stronger in a deficit, and training still attenuates lean mass loss.
• Protein 1.2-1.6 g/kg body weight per day for general weight loss, with 1.6-2.0 g/kg recommended on a GLP-1 per Stefanakis 2024^[8]. Distribute across 3-4 meals of 25-40 g protein each.
• DXA scan at baseline and every 6 months is the gold standard for tracking. BIA scales are the next-best home option. Tape measurements plus progress photos are the cheapest objective adjunct.
• Adults over 65 and perimenopausal women should treat DXA monitoring and structured resistance training as standard, not optional. The clinical stakes of lean mass loss are highest in these populations.

Related research and tools

• Ozempic muscle loss & lean mass protection evidence — the sister article on semaglutide, with the same DXA substudy framework applied to the STEP program.
• Semaglutide muscle mass loss evidence — broader semaglutide lean-mass coverage including STEP-2 (type 2 diabetes) and STEP-5 (long-term maintenance).
• Exercise pairing on a GLP-1 (Pilates, walking, HIIT, resistance training) — the broader evidence map on exercise modalities and lean mass preservation across all GLP-1 therapies.
• GLP-1 + creatine for lean mass preservation — the dedicated creatine deep-dive, including the loading-phase guidance for GLP-1 patients during the dose- titration window.
• When to drink protein shakes for weight loss (female- focused evidence) — protein timing for perimenopausal women on a GLP-1, the sister article being written in this session.
• Best protein powder for weight loss on a GLP-1 — product selection criteria (NSF Certified for Sport, USP Verified, third-party testing), whey vs casein vs plant evidence, and protein timing for GLP-1 users.
• Tirzepatide vs semaglutide head-to-head — total weight loss comparison (SURMOUNT-1 vs STEP-1) and indirect body-composition inference.
• Retatrutide vs tirzepatide head-to-head evidence — the triple-agonist comparator, including the body composition substudy data from Coskun 2025.
• Bariatric surgery vs GLP-1 decision guide — the full comparison for patients weighing surgical vs pharmacological weight loss.
• Mounjaro and Zepbound FDA prescribing information explained — the labeled adverse reactions, contraindications, and warnings for tirzepatide as approved by the FDA.
• GLP-1 protein & macro calculator — personalized protein, fat, and carb targets based on body weight, activity, and weight-loss goal.

Important disclaimer. This article is educational and does not constitute medical advice, an exercise prescription, or a nutritional prescription. Patients with cardiovascular disease, joint pathology, kidney disease, eating disorders, or other conditions limiting exertion or affecting protein metabolism should consult a clinician (and ideally a credentialed exercise physiologist or registered dietitian) before starting any new exercise or supplementation program. The SURMOUNT-1 DXA substudy^[1] reports body composition data on tirzepatide in adults with obesity without type 2 diabetes; the SURPASS-3 MRI substudy^[7] reports body fat distribution data on tirzepatide in adults with type 2 diabetes. Cross-population extrapolation between these cohorts is reasonable but not identical. Every primary source cited here was independently verified against the live PubMed E-utilities API on 2026-05-24.